GSK-3 Inhibitors: Anti-Diabetic Treatment Associated with Cardiac Risk?

Early cardiac changes induced by a hypercaloric Western-type diet in “subclinical” obesity

(2016) Nádia Gonçalves et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts

(2016) B. Huisamen et al.   CARDIOVASCULAR DRUGS AND THERAPY

GSK-3: Functional Insights from Cell Biology and Animal Models

(2011) Oksana Kaidanovich-Beilin et al.   Frontiers in Molecular Neuroscience

Glycogen Synthase Kinase-3β Regulates Post–Myocardial Infarction Remodeling and Stress-Induced Cardiomyocyte Proliferation In Vivo

(2010) Kathleen C. Woulfe et al.   CIRCULATION RESEARCH

GSK-3α directly regulates β-adrenergic signaling and the response of the heart to hemodynamic stress in mice

(2010) Jibin Zhou et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting GSK-3 family members in the heart: A very sharp double-edged sword

(2010) Hui Cheng et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes

(2008) Katrina MacAulay et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Unique and Overlapping Functions of GSK-3 Isoforms in Cell Differentiation and Proliferation and Cardiovascular Development

(2008) Thomas Force et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deletion of GSK-3β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation

(2008) Risto Kerkela et al.   JOURNAL OF CLINICAL INVESTIGATION